{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:12:27Z","timestamp":1767651147797,"version":"3.41.2"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>We present a description of pediatric pneumology biological medications and other target therapies. The article aims at introducing the importance of a molecular approach to improve treatments. The first item treated was T2-High asthma and its current biological treatment and prescribing indications to propose a flow-chart to guide the clinical choice. Molecular rationales of such treatments are used to introduce a more general description of the biological and molecular approach to target therapies application. We introduce a general interpretation approach to neutrophilic asthma using the molecular plausibility one in order to propose possible future treatments mainly targeting interleukin-1 (IL-1), IL-17, IL-12, and IL-23. Indeed, cytokines can be excellent targets for several biological treatments. Downregulation of specific cytokines can be crucial in treating autoinflammatory and rheumatological diseases with a pulmonary involvement. Such conditions, although rare, should be early recognized as they can involve significant improvement with a properly targeted therapy. We face these conditions in a cherry-picking fashion picturing SAVI (STING-associated vasculopathy with onset in infancy), CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature), and COPA (coat proteins alpha syndrome) syndrome pulmonary involvement. Such examples are functional to introduce molecular-based approach for patients with rare conditions. Molecular plausibility can be highly valuable in treating patients with not-approved but possibly highly effective therapies. Due to the rarity of these conditions, we stress the concept of basket trials using the example of cytokinin-directed immunosuppressive treatment. Lastly, we provide an example of augmentative therapy using the alpha1 antitrypsin deficiency as a model. In summary, the article presents a collection of the most recent achievements and some possible future developments of target therapies for pediatric pulmonary conditions.<\/jats:p>","DOI":"10.3389\/fped.2022.837667","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T06:01:31Z","timestamp":1644904891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Biological Treatments and Target Therapies for Pediatric Respiratory Medicine: Not Only Asthma"],"prefix":"10.3389","volume":"10","author":[{"given":"Sergio","family":"Ghirardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Mazzolai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Petreschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Lucia","family":"Ciofi degli Atti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Cutrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/pai.13007","article-title":"New perspectives of childhood asthma treatment with biologics","volume":"30","author":"Just","year":"2019","journal-title":"Pediatr Allergy Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jaip.2019.03.008","article-title":"Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent","volume":"7","author":"Krings","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.anai.2016.05.016","article-title":"Characterization of asthma endotypes: implications for therapy","volume":"117","author":"Stokes","year":"2016","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/07853890701449354","article-title":"Triggers of IgE class switching and allergy development","volume":"39","author":"Poulsen","year":"2007","journal-title":"Ann Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0161-5890(02)00072-X","article-title":"Macromolecular protein signaling complexes and mast cell responses: a view of the organization of IgE-dependent mast cell","volume":"38","author":"Rivera","year":"2002","journal-title":"signaling Mol Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S263","DOI":"10.1513\/AnnalsATS.201403-097AW","article-title":"Type-2 innate lymphoid cells in asthma and allergy","volume":"11","author":"McKenzie","year":"2014","journal-title":"Ann Am Thorac Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"GH Koppelman","volume":"386","author":"Brusselle","year":"2022","journal-title":"Biologic Therapies for Severe Asthma."},{"key":"B11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003559.pub4","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1701655","DOI":"10.1183\/13993003.01655-2017","article-title":"Precision medicine in airway diseases: moving to clinical practice","volume":"50","author":"Bafadhel","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Ikeda","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Pouliquen","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet."},{"key":"B21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","article-title":"Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet (London, England)."},{"key":"B25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/dtb.2017.12.0557","article-title":"Anti-IL-5 therapies for asthma","volume":"55","author":"Farne","year":"2017","journal-title":"Drug Ther Bull."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1900563","DOI":"10.1183\/13993003.00563-2019","article-title":"Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD","volume":"55","author":"Osei","year":"2020","journal-title":"Eur Respir J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11882-011-0210-y","article-title":"The Potential Role of IL-17 in Severe Asthma","volume":"11","author":"Wang","year":"2011","journal-title":"Curr Allergy Asthma Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-014-0163-5","article-title":"Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA\/IL-1\u03b2","volume":"16","author":"Gao","year":"2015","journal-title":"Respir Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2014.07.039","article-title":"Interleukin-1 receptor antagonist reduces endotoxin-induced airwayinflammation in healthy volunteers","volume":"135","author":"Hernandez","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/mrm.2015.275","article-title":"Tailored therapy for severe asthma","volume":"10","author":"Menzella","year":"2015","journal-title":"Multidiscip Respir Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/cei.12400","article-title":"Functional relevance of NLRP3 inflammasome-mediated interleukin (IL)-1\u03b2 during acute allergic airway inflammation","volume":"178","author":"Straubinger","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"Baeten","year":"2013","journal-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1016\/j.celrep.2019.07.039","article-title":"Activation and In Vivo Evolution of the MAIT Cell Transcriptome in Mice and Humans Reveals Tissue Repair Functionality","volume":"28","author":"Hinks","year":"2019","journal-title":"Cell Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"00364","DOI":"10.1183\/23120541.00364-2019","article-title":"Hinks TSC. The role of interleukin-17 in asthma: a protective response?","volume":"6","author":"Hynes","year":"2020","journal-title":"ERJ Open Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev-pathol-011110-130318","article-title":"The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs and Skin","volume":"8","author":"Weaver","year":"2013","journal-title":"Annu Rev Pathol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.coi.2008.09.004","article-title":"The IL-17 cytokine family and their role in allergic inflammation","volume":"20","author":"Wang","year":"2008","journal-title":"Curr Opin Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13223-020-00504-3","article-title":"Relationship between Th17-mediated immunity and airway inflammation in childhood neutrophilic asthma","volume":"17","author":"Wei","year":"2021","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s12325-020-01352-8","article-title":"Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in europe: baseline data from SERENA study","volume":"37","author":"Kiltz","year":"2020","journal-title":"Adv Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Singh D. Risankizumab in Severe Asthma\u2014A Phase 2a, Placebo-Controlled Trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N Engl J Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"170100","DOI":"10.1183\/16000617.0100-2017","article-title":"Chronic interstitial lung disease in children","volume":"27","author":"Griese","year":"2018","journal-title":"European Respiratory Review."},{"key":"B45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.coi.2010.12.015","article-title":"Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses","volume":"23","author":"Barber","year":"2011","journal-title":"Curr Opin Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.tim.2017.05.008","article-title":"The emerging roles of STING in bacterial infections","volume":"25","author":"Marinho","year":"2017","journal-title":"Trends Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm-20-6198","article-title":"STING-associated vasculopathy with onset in infancy: a familial case series report and literature review","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a Vascular and Pulmonary Syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2017.00927","article-title":"Syndrome As a Paradigm of Proteasome-Related Autoinflammation","volume":"8","author":"Torrelo","year":"2017","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S153600","article-title":"Genetics of COPA syndrome","volume":"12","author":"Kumrah","year":"2019","journal-title":"Appl Clin Genet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/jmedgenet-2018-105560","article-title":"Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features","volume":"56","author":"Taveira-DaSilva","year":"2019","journal-title":"J Med Genet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd1343","article-title":"Small-molecule inhibitors of protein\u2013protein interactions: progressing towards the dream","volume":"3","author":"Arkin","year":"2004","journal-title":"Nat Rev Drug Discov."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00109-016-1465-5","article-title":"Insights from mendelian interferonopathies: comparison of CANDLE, SAVI with AGS, monogenic lupus","volume":"94","author":"Kim","year":"2016","journal-title":"J Mol Med (Berl)."},{"key":"B57","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3266","article-title":"Canakinumab (ACZ885, a fully human IgG1 anti-IL-1\u03b2 mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)","volume":"13","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Arthritis Res Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe \u03b11 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet (London, England)."},{"key":"B60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ppul.1950110306","article-title":"Hyperinflation in children with liver disease due to alpha-1-antitrypsin deficiency","volume":"11","author":"Hird","year":"1991","journal-title":"Pediatr Pulmonol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/adc.85.1.2","article-title":"Alpha-1 antitrypsin deficiency","volume":"85","author":"Primhak","year":"2001","journal-title":"Arch Dis Child."},{"key":"B62","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1183\/09031936.00029809","article-title":"Intravenous \u03b11-antitrypsin in a child with deficiency and severe lung disease","volume":"34","author":"Griese","year":"2009","journal-title":"Eur Respir J."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.837667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:55:59Z","timestamp":1700229359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.837667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":62,"alternative-id":["10.3389\/fped.2022.837667"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.837667","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"article-number":"837667"}}